SOLV at a glance
Solventum (SOLV, SEC CIK 1964738) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and Form 4 insider filings as recently as September 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Solventum (SOLV) reported revenue of $8.3 billion (up 0.9% from FY2024) and net income of $1.6 billion. Diluted EPS was $8.88.
- As of June 30, 2026, 48 institutional investment managers tracked by SignalX reported holding Solventum (SOLV) shares worth $4.6 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $8.3B
- +0.9% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 48 funds
- $4.6B · +4 vs prior quarter
- Latest 8-K
- Aug 5, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Management Discussion & Analysis
- Revenue $8,325M, up 0.9% YoY ($71M increase); organic growth 3.3%, offset by -3.0% divestiture impact from Purification & Filtration sale
- Operating margin 26.2% vs 12.6% in 2024 (includes $1.5B gain on P&F sale); SG&A 37.0% vs 33.7%; R&D 8.9% vs 9.4%
- Best segment: Health Information Systems, operating margin 36.5% vs 33.0%, sales +4.1% to $1,360M; worst: MedSurg margin 16.8% vs 19.1%, despite 3.9% sales growth to $4,817M
- Investing activities $2,797M inflow (vs -$380M in 2024) driven by ~$4B P&F sale proceeds; financing outflows -$3,057M including $2.0B senior note repayment and $1,070M term loan repayments; cash position $878M at year-end
- Key risks: tariff impact ~$55M on product costs, ongoing 3M supply agreement mark-ups, debt servicing burden, and brand transition from 3M; no explicit forward guidance provided
Risk Factors
- 3M sole-source supplier for materials tied to ~$3B revenue (FY2025); ~$2B from proprietary material with no identified substitute or internal manufacturing capability
- $5B outstanding debt post-spin as of Dec 31, 2025; constrains capital allocation, raises downgrade risk, and limits strategic flexibility
- U.S.-China trade tensions and tariffs actively impacting Solventum and suppliers; further escalation cited as material risk to global operations
- AI-enabled new entrants threatening Health Information Systems segment specifically; failure to match competitor AI integration risks customer loss
- PFAS indemnification from 3M expires after 2025 product sales; ongoing PFAS use in components (wound therapy, temp management devices) creates unindemnified regulatory and litigation exposure
Business Overview
- Global healthcare company (~20,000 employees, ~$0 revenue figures disclosed) across three segments: MedSurg 57.9%, Health Information Systems 16.3%, Dental Solutions 16.2% of 2025 sales
- Two major portfolio moves in 2025: acquired Acera Surgical (bioscience, adds synthetic tissue matrices) and divested Purification & Filtration business to Thermo Fisher Scientific
- Still separating from 3M parent: actively transitioning off 3M infrastructure under Transition and Distribution Agreement and Transition Contract Manufacturing Agreement, a key ongoing operational risk
- R&D team of ~2,000 employees; sales presence in 90+ countries with ~40% of workforce having 10+ years tenure, signaling stable legacy talent base during post-spin transition
- U.S. Supreme Court ruled Feb 20, 2026 that IEEPA does not authorize presidential tariffs: Solventum explicitly flagged potential tariff recovery but stated financial impact "cannot be reasonably estimated," a rare forward-looking legal disclosure embedded in the business section
AI summary of the SOLV 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Q2 revenue $2.209B, up 2.2% YoY from $2.161B
- Operating margin 8.2% vs 9.9% YoY; cost of product 47.5% vs 51.9%
- Best segment Dental Solutions: revenue $396M, up 17.0%; margin 33.0% vs 28.5%
- Worst segment Health Information Systems: revenue $354M, up 4.4%; clinician productivity declines amid changing market conditions
- Cash $403M vs $878M at December 31; six-month operating cash flow $38M vs $198M, with $350M financing outflows
- Q3 headwind: customer inventory normalization expected after $125M of ERP-related advanced orders in Q2
Risk Factors
- Newly added strategic-review risk: health information systems alternatives may fail, be abandoned, or remain incomplete
- Most material operational risk: strategic review may divert management attention and create customer and employee uncertainty
- Financial risk: review-related costs may arise regardless of transaction completion
- Near-term performance risk: inability to realize strategic, operational, or financial benefits from any alternative
AI summary of the SOLV 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Filing contains only signature and cover-page information, not the Item 2.02 earnings disclosure
- CFO Wayde McMillan signed the report on August 5, 2026
Item 7.01: Regulation FD Disclosure
- Solventum issued an August 5, 2026 press release under Regulation FD
- Exhibit 99.1 contains the substantive disclosure investors should review
Item 8.01: Other Events
- Filing contains only the signature page and Cover Page Interactive Data File
- No substantive Other Events disclosure affecting Solventum or shareholders
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Neil Zieselman appointed Controller and Chief Accounting Officer effective August 10, 2026
- Replaces retiring Mary Wilcox and becomes Solventum’s SEC Principal Accounting Officer
AI summaries of SOLV 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SOLV
Don't miss the next SOLV filing
- Alerts as it files. A push when SOLV files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SOLV, by share count.
- Ask anything. An AI agent that reads every SOLV filing and answers with sources.
SOLV alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Hanson Bryan C | M | Sep 1, 2026 | 67,261 | - |
| Hanson Bryan C | F | Sep 1, 2026 | 26,468 | $90.95 |
| Hanson Bryan C | M | Sep 1, 2026 | 67,261 | - |
| Zieselman Neil Craig | A | Aug 17, 2026 | 6,911 | - |
| WEILAND JOHN H | A | May 15, 2026 | 3,300 | - |
| Harris Bernard A Jr | A | May 15, 2026 | 3,300 | - |
| EISENBERG GLENN A | A | May 15, 2026 | 3,300 | - |
| DeVore Susan D. | A | May 15, 2026 | 3,300 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $8.3B | $8.3B |
| Gross Profit | - | $4.6B | $4.5B |
| Operating Income | - | $1.0B | $2.2B |
| Net Income | - | $479.0M | $1.6B |
| Gross Margin | - | 55.6% | 53.5% |
| Op. Margin | - | 12.6% | 26.2% |
| Net Margin | - | 5.8% | 18.7% |
| Balance Sheet | |||
| Total Assets | $13.9B | $14.5B | $14.3B |
| Equity | - | $3.0B | $5.0B |
| ROE | - | 16.2% | 30.8% |
| Per Share | |||
| EPS | - | $2.76 | $8.88 |
| Cash Flow | |||
| Operating CF | - | $1.2B | $369.0M |
| CapEx | $290.0M | $380.0M | $379.0M |
Source: XBRL data in Solventum (SOLV)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate SOLV share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 48 | $4.59B |
| Q1 2026 | 44 | $3.90B |
| Q4 2025 | 43 | $4.60B |
| Q3 2025 | 43 | $4.34B |
| Q2 2025 | 39 | $4.25B |
| Q1 2025 | 39 | $3.62B |
| Q4 2024 | 34 | $2.89B |
| Q3 2024 | 34 | $1.76B |
- Dimensional Fund Advisors+1.04M (+135%)
- Millennium Management+659.6K (+122%)
- D.E. Shaw & Co+380.5K (+261%)
- AQR Capital Management+352.1K (+48%)
- FMR LLC (Fidelity)+209.1K (+11%)
- State Street Corp−768.3K (-12%)
- BlackRock−717.1K (-7%)
- Citadel Advisors LLC−500.8K (-84%)
- Invesco Ltd−480.0K (-13%)
- Morgan Stanley−229.8K (-13%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 324 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SOLV filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 8-K | Jul 20, 2026 | - | Analysis | - |
| 8-K | Jun 5, 2026 | - | Analysis | |
| 8-K | May 27, 2026 | - | Analysis | |
| 8-K | May 20, 2026 | - | Analysis | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 15, 2026 | - | - | |
| 4 | May 15, 2026 | - | - | |
| 4 | May 15, 2026 | - | - | |
| 4 | May 15, 2026 | - | - | |
| 4 | May 15, 2026 | - | - | |
| 4 | May 15, 2026 | - | - | |
| 4 | May 15, 2026 | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
SOLV SEC filings: frequently asked questions
Which institutions hold SOLV stock?
As of June 30, 2026, the largest Solventum (SOLV) holders among the 13F filers tracked by SignalX were BlackRock ($753.1 million), Vanguard Capital Management LLC ($742.6 million), Trian Fund Management ($635.5 million), Vanguard Portfolio Management LLC ($488.3 million), State Street Corp ($435.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SOLV's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Solventum (SOLV) reported revenue of $8.3 billion (up 0.9% from FY2024) and net income of $1.6 billion. Diluted EPS was $8.88. The figures come from the XBRL data in the 10-K.
What are the main risks in SOLV's latest 10-K?
In the 10-K filed February 27, 2026, Solventum (SOLV) flagged: 3M sole-source supplier for materials tied to ~$3B revenue (FY2025); ~$2B from proprietary material with no identified substitute or internal manufacturing capability. $5B outstanding debt post-spin as of Dec 31, 2025; constrains capital allocation, raises downgrade risk, and limits strategic flexibility. (AI summary of the Risk Factors section.)
What did SOLV report in its latest 8-K?
Solventum (SOLV) filed an 8-K on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Filing contains only signature and cover-page information, not the Item 2.02 earnings disclosure.
What are the latest SOLV SEC filings?
Solventum (SOLV) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and a Form 4 insider filing on September 3, 2026.
What is SOLV's SEC CIK number?
Solventum (SOLV)'s SEC Central Index Key (CIK) is 1964738. EDGAR lists every SOLV filing under that number.
Ask anything about SOLV
The research agent reads SOLV's filings, financials, insider trades and 13F holders, then answers with sources.